Kymera Therapeutics, Inc.
KYMR · XNASCIK 1815442fmd_15Z6766MHY6T2ZR7KJDE8GNFWCManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 34 | 73 | 47 | 79 | 47 | 39 |
| Cost of revenue | – | – | – | 47 | 79 | 47 | 39 |
| Gross profit | – | – | – | 0 | 0 | 0 | 0 |
| Research and development | 37 | 62 | 137 | 164 | 189 | 240 | 317 |
| Total operating expenses | 45 | 80 | 173 | 208 | 244 | 309 | 389 |
| Operating income | (42) | (46) | (101) | (161) | (166) | (262) | (349) |
| Other non-operating income (expense) | 1 | 1 | 0 | 6 | 19 | 38 | 38 |
| Income before taxes | – | – | – | – | – | – | (311) |
| Income tax expense | 0 | 0 | 0 | 0 | – | – | 0 |
| Net income from continuing operations | – | – | – | – | – | – | (311) |
| Net income | (41) | (46) | (100) | (155) | (147) | (224) | (311) |
| Net income to common shareholders | (41) | (55) | (100) | (155) | (147) | (224) | (311) |